Predict your next investment

Walvax Biotechnology company logo
Corporation
HEALTHCARE | Drug Development
walvax.com

See what CB Insights has to offer

Investments

2

Portfolio Exits

2

Funds

1

Partners & Customers

5

Service Providers

3

About Walvax Biotechnology

Walvax Biotechnology (沃森生物) is a modern biological pharmaceutical enterprise engaged in R & D, production, and sales of bio-medicine products.

Walvax Biotechnology Headquarter Location

19/F Bldg.9A, Dingyi Tiancheng Residential Quarter Keyuan Road No. 99, Yunnan Province

Kunming, 650106,

China

+ (86) 871-68312659

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Walvax Biotechnology Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Walvax Biotechnology Rank

Latest Walvax Biotechnology News

HPV Vaccine Market: 5.73B by 2028, Human Papillomavirus Vaccine Market Growing at 5% CAGR Lead by 9-Valent HPV Vaccine Segment, Global Analysis by The Insight Partners

Jun 17, 2022

Global Human Papillomavirus (HPV) Vaccines Market: Competitive Landscape and Key Developments GSK; Innovax; Walvax; Serum Institute of India Pvt., Ltd.; Vaccitech; Innovio Pharmaceuticals; Merck & Co., Inc.; 2A Pharm; ChengDu Institute of Biological Products Co., Ltd.; Sanofi; R-Pharm; Shanghai Bowei; and BioLeaders implemented various organic strategies, such as partnerships and collaborations, which bought dynamic improvements in the global human papillomavirus (HPV) vaccines market. Various companies are also adopting organic strategies, such as product launches and expansions, to expand their business and enhance geographic presence. Additionally, product launch and expansion help market players strengthen their customer base and expand the product portfolio. Place Your Inquiry Before Buying: https://www.theinsightpartners.com/inquiry/TIPRE00029411/ In May 2022, China’s National Medical Products Administration (NMPA) approved GlaxoSmithKline’s (GSK) two-dose vaccine schedule, Cervarix, for girls between 9 to 14 years to prevent cervical cancer. Cervarix is a recombinant, noninfectious, AS04-adjuvanted HPV bivalent (types 16, 18) vaccine. In May 2022, Serum Institute of India announced the development of a tetravalent HPV vaccine including L1 VLPs of serotypes 6,11,16,18, which is expected to give a coverage of ~90% against papillomavirus. The vaccine is currently under development. In March 2022, China’s NMPA approved Walvax Biotechnology Co. Ltd.’s human papillomavirus (HPV) bivalent vaccine to be used against HPV types 16 and 18 to prevent cervical cancer. In November 2021, Merck announced the successful completion of the acquisition of Acceleron Pharma Inc. In June 2021, R-Pharm Group (a Russian biotech firm) and Beijing Health Guard Biotechnology entered into a license agreement on the development and commercialization of a 9-valent human papillomavirus (HPV) vaccine in Russia. The agreement provides for the conduct of Phase III clinical trials and registration of the nonavalent HPV vaccine in Russia and the localization of production of ready-to-use dosage form at R-Pharm's facility. Connect with Our Research Analyst On: https://www.theinsightpartners.com/speak-to-analyst/TIPRE00029411 In February 2021, QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies. Human Papillomavirus (HPV) Vaccines Market: Key Insights The human papillomavirus (HPV) vaccine market growth driven by the increasing prevalence of HPV associated diseases and rising initiatives taken by global health organizations. However, the high cost of HPV vaccines hinders the global market growth. Global Human Papillomavirus (HPV) Vaccines Market: Key Insights – Future Trends Companies are undertaking many research and development activities to introduce advanced HPV tests. For instance, in May 2021, BD, a leading medical technology company, launched the first CE marked assay for HPV screening from at-home self-collected vaginal samples. This allows laboratories to process self-collected samples via a BD diluent tube. At-home collection of samples will help address the urgent public health challenge of reaching out to women who do not attend routine cervical cancer screening. Further, in September 2020, US Food and Drug Administration (FDA) approved the expanded use of F. Hoffmann-La Roche Ltd, CINtec PLUS Cytology, the first triage test based on biomarker technology for women whose cervical cancer screening results are positive for high-risk types of human papillomavirus (HPV). The CINtec PLUS Cytology test identifies the simultaneous presence of the two biomarkers -- p16 and Ki-67 in a single cell. This abnormality is associated with HPV infections that progress to pre-cancer or cancer if not treated. A positive result of these two biomarkers is more significantly at risk for disease. Such robust developments in HPV diagnostics tests are likely to reshape the HPV vaccines market during the forecast period. Global Human Papillomavirus (HPV) Vaccines Market: Segmental Overview Based on type, the global human papillomavirus (HPV) vaccines market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment holds the largest share of the market in 2022. In contrast, the 9-valent HPV vaccine segment is anticipated to register the highest CAGR of 5.4% in the market during the forecast period. The quadrivalent human papillomavirus (HPV) vaccine protects against infection with HPV types 6, 11, 16, and 18, which are responsible for 70% to 80% of cervical cancers and at least 90% of cases of genital warts. The vaccine reduces the risk of genital warts and precursor lesions of cervical, vaginal and vulvar cancers caused by the virus types in the vaccine. It is a prophylactic vaccine — there is no evidence that it treats infection or prevents disease caused by pre-existing HPV infection. The quadrivalent HPV (types 6, 11, 16, and 18) recombinant vaccine is available under the National Immunization Program (NIP) for females aged 12–26 years. Buy Premium Copy of Human Papillomavirus (HPV) Vaccine Market Size, Share, Revenue, Strategic Insights and Forecasts 2022-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00029411/ In the per-protocol population, the quadrivalent HPV vaccine had 100% efficacy against surrogate markers of cervical cancer caused by HPV types included in the vaccine. The quadrivalent HPV vaccine is approved (but not funded under the NIP) for boys aged 9–15 years to prevent infection with HPV types 6, 11, 16, and 18. Owing to the above factors, demand for quadrivalent HPV vaccines is expected to increase during the forecast period. Browse Adjoining Reports: Human Papillomavirus (HPV) and Cytomegalovirus (CMV) Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Type (HPV Therapeutics, CMV Therapeutics); Application (HPV Therapeutics Application, CMV Therapeutics Application) and Geography Diagnostic Testing of STDs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Type (Chlamydia, Gonorrhea, Herpes simplex virus, Syphilis, Human papillomavirus (HPV) and other diseases); Testing (Laboratory Testing, Point of care (POC) Testing) and Geography Infectious Disease Diagnostics Market Forecast to 2028- COVID-19 Impact, and Global Analysis - by Product (Kits and Reagents, Instruments, and Software and Service  ss), Disease Indication [HIV, Hepatitis, Healthcare- Associated Infections (HAIs), Human Papillomavirus (HPV), Tuberculosis (TB), Influenza, and Others Disease Indications  ], Technology (Immunodiagnostics, Polymerase Chain Reaction, Next Generation Sequencing, Clinical Microbiology, and Others), Testing Type (Laboratory Testing and, Point of Care Testing), End User (Hospitals and Clinics, Pathology or Diagnostic Laboratories, Research Institutes, Home-Care Settings, and Others End User), and Geography Cervical Cell Collector Papette Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product ( Cervex-Brush, Cervical Spatulas, Endocervical Sampling Kits, Others ); Application ( As HPV Testing, Conventional Cytology, Liquid-Based Cytology, Others ), and Geography Cervical Cancer Diagnostic Testing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (PAP Testing, HPV Testing, Colposcopy, Cervical Biopsies, Cystoscopy, and Others) and Service Provider (Diagnostics and Research Laboratories, Hospitals and Clinics, Specialty Clinics, and Home Care services) and Geography Warts Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Common Warts, Genital Warts, Flat Warts, and Others), Treatment (Physical Destruction, Immunomodulation, and Chemical Destruction), and End User (Hospitals, Homecare, Specialty Clinics, and Others) About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer Joshi

Walvax Biotechnology Investments

2 Investments

Walvax Biotechnology has made 2 investments. Their latest investment was in Sirnaomics as part of their Series D on October 10, 2020.

CBI Logo

Walvax Biotechnology Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/23/2020

Series D

Sirnaomics

$105M

Yes

29

6/25/2019

Unattributed

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/23/2020

6/25/2019

Round

Series D

Unattributed

Company

Sirnaomics

Subscribe to see more

Amount

$105M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

29

10

Walvax Biotechnology Portfolio Exits

2 Portfolio Exits

Walvax Biotechnology has 2 portfolio exits. Their latest portfolio exit was Sirnaomics on December 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/30/2021

IPO

$99M

Public

4

10/7/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/30/2021

10/7/2020

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

4

10

Walvax Biotechnology Acquisitions

1 Acquisition

Walvax Biotechnology acquired 1 company. Their latest acquisition was Genor Biopharma on December 31, 2013.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/31/2013

Series B

$99M

$865.11M

Corporate Majority

2

Date

12/31/2013

Investment Stage

Series B

Companies

Valuation

$99M

Total Funding

$865.11M

Note

Corporate Majority

Sources

2

Walvax Biotechnology Fund History

1 Fund History

Walvax Biotechnology has 1 fund, including Zhuhai Hengqin Walvax Investment Fund (珠海横琴沃森投资基金).

Closing Date

Fund

Fund Type

Status

Amount

Sources

Zhuhai Hengqin Walvax Investment Fund (珠海横琴沃森投资基金)

1

Closing Date

Fund

Zhuhai Hengqin Walvax Investment Fund (珠海横琴沃森投资基金)

Fund Type

Status

Amount

Sources

1

Walvax Biotechnology Partners & Customers

5 Partners and customers

Walvax Biotechnology has 5 strategic partners and customers. Walvax Biotechnology recently partnered with Honeywell Process Solutions on March 3, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

3/14/2022

Vendor

United States

A closer look at Honeywell’s and Walvax Biotech’s mRNA COVID-19 vaccine plant partnership

Walvax and Honeywell Process Solutions partnered to build China 's first mRNA COVID-19 vaccine plant .

1

4/29/2021

Supplier

United States

Subscribe to see more

Subscribe to see more

10

9/2/2020

Client

Germany

Subscribe to see more

Subscribe to see more

10

10/18/2016

Partner

China

Subscribe to see more

Subscribe to see more

10

9/8/2015

Vendor

United States

Subscribe to see more

Subscribe to see more

10

Date

3/14/2022

4/29/2021

9/2/2020

10/18/2016

9/8/2015

Type

Vendor

Supplier

Client

Partner

Vendor

Business Partner

Country

United States

United States

Germany

China

United States

News Snippet

A closer look at Honeywell’s and Walvax Biotech’s mRNA COVID-19 vaccine plant partnership

Walvax and Honeywell Process Solutions partnered to build China 's first mRNA COVID-19 vaccine plant .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Walvax Biotechnology Service Providers

3 Service Providers

Walvax Biotechnology has 3 service provider relationships

Service Provider

Associated Rounds

Provider Type

Service Type

Commercial Bank

General Business Banking

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Service Provider

Subscribe to see more

Subscribe to see more

Associated Rounds

Provider Type

Commercial Bank

Subscribe to see more

Subscribe to see more

Service Type

General Business Banking

Subscribe to see more

Subscribe to see more

Partnership data by VentureSource

Walvax Biotechnology Team

3 Team Members

Walvax Biotechnology has 3 team members, including current Chief Executive Officer, Yunchun Li.

Name

Work History

Title

Status

Yunchun Li

Chief Executive Officer

Current

Yunhua Wang

Chief Financial Officer

Current

Zhen Huang

Chief Technology Officer

Current

Name

Yunchun Li

Yunhua Wang

Zhen Huang

Work History

Title

Chief Executive Officer

Chief Financial Officer

Chief Technology Officer

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.